MBL obtained manufacturing and marketing approval on September 14, 2022 for its new GLINE-SARS-CoV-2&FluA+B, a simple test kit that simultaneously detects both the SARS-CoV-2 antigen and influenza virus antigen in a single test cassette. Sales will begin on September 30.
This kit detects the SARS-CoV-2 antigen, influenza A virus antigen, and influenza B virus antigen in nasopharyngeal or nasal swab fluid using an immunochromatographic* method.
*Immunochromatography: A method to test for viral infection by dropping a sample into a kit. Since it uses capillary action, no machine is required for the test, and the test can be performed visually. It is a simple and rapid method that can determine the result within 15~20 minutes after specimen is dropped into the reaction cassette.
A single test cassette is used to test for influenza A and B viruses as well as novel coronaviruses.
The ability to perform both tests with a single specimen collection reduces the burden on patients at the time of sample collection, as well as the testing workload for healthcare professionals.
Contact details
-
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com
Related topics
Related news
MBL Co-sponsors a Seminar on MEBRIGHT™ genitalium Plus DR Kit at the 98th JAID / the 72nd JSC Conference
MBL to co-sponsor a seminar on MEBRIGHT™ genitalium Plus DR Kit at the 98th JAID/72nd JSC Conference, focusing on STD treatment advancements. Learn more on June 27th, 2024.
MBL announces exclusive license agreement for Anti-Integrin αvβ6 Antibody with Immune-related Adverse Events colitis
MBL has announced that it has entered into an exclusive license agreement with Kyoto University and Kindai University regarding the detection of Anti-Integrin αvβ6 autoantibodies as an indicator of...
MEBGEN™ BRAF 2 Kit Receives MHLW Approval as a Companion Diagnostic for Use with Patients with Thyroid Cancer
With this approval, the MEBGEN™ BRAF 2 Kit is expected to contribute to the timely personalized treatment for patients with radically unresectable thyroid cancer based on the presence or absence of...
Notice of Approval for First-Class Marketing License for Medical Devices
With the acquisition of the First-Class Marketing License for Medical Devices, MBL will be able to market highly controlled medical devices, including genetic testing systems using NGS.
Launch of a New Chemiluminescence Immunoassay Analyzer “iStar500”
The iStar is a highly automated mono-test analyzer based on CLIA technology. The compact & integrated design, combined with highly sensitive CLIA technology, makes it an ideal choice for emergency ...